z-logo
Premium
Coadministration of lorcaserin and phentermine for weight management: A 12‐week, randomized, pilot safety study
Author(s) -
Smith Steven R.,
Garvey W. Timothy,
Greenway Frank L.,
Zhou Sharon,
Fain Randi,
Pilson Robert,
Fujioka Ken,
Aronne Louis J.
Publication year - 2017
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.21811
Subject(s) - phentermine , discontinuation , medicine , tolerability , adverse effect , weight loss , randomized controlled trial , anesthesia , obesity
Objective To assess the short‐term tolerability of lorcaserin alone or with two dose regimens of phentermine. Methods This was a 12‐week, randomized, double‐blind, pilot safety study of N  = 238 nondiabetic patients with obesity or overweight with ≥1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 mg twice daily (LOR BID+PHEN BID). Patients reporting ≥ 1 of 9 potentially serotonergic adverse events (AEs), mean weight loss (WL), and ≥5% WL are reported. Results N  = 238 were randomized, and N  = 235 were treated. N  = 94 reported potentially serotonergic AEs: 37.2% LOR BID, 42.3% LOR BID+PHEN QD, and 40.5% LOR BID+PHEN BID. AEs leading to discontinuation were reported approximately twice as often in the LOR BID+PHEN BID group versus the LOR BID group. Mean WL was 3.5 kg/3.3%, 7.0 kg/6.7%, and 7.6 kg/7.2% for LOR BID, LOR BID+PHEN QD, and LOR BID+PHEN BID, respectively. At least 5% WL was achieved by 28.2% LOR BID, 59.0% LOR BID+PHEN QD ( P  = 0.0002 vs. LOR BID), and 70.9% LOR BID+PHEN BID ( P  < 0.0001 vs. LOR BID) patients. Conclusions Phentermine added to lorcaserin enhanced short‐term weight loss but did not increase incidence of potentially serotonergic AEs; however, phentermine twice daily increased discontinuation compared to both lorcaserin alone and lorcaserin plus phentermine once daily.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here